Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Fusion protein or fusion polypeptide
Reexamination Certificate
2006-10-10
2006-10-10
O'Hara, Eileen B. (Department: 1646)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Fusion protein or fusion polypeptide
C424S198100, C530S351000, C530S399000, C514S012200, C526S085000, C435S320100, C435S325000, C435S069500, C435S069700
Reexamination Certificate
active
07118752
ABSTRACT:
A method is described for using an a-type or b-type E domain of the human or trout IGF peptide for the inhibition of proliferation and invasiveness of a broad spectrum of malignant cells and for the inhibition of angiogenesis. The peptide species can be a homologue of the E-domain of IGF-1 or a fusion protein comprising the E-domain of IGF-1. It can be administered to one or more malignant cells in a pharmaceutically acceptable composition, or alternatively, can be administered to one or more malignant cells by transforming the cells with exogenous nucleic acid that results in the expression of the E domain of IGF-1 in the cell.
REFERENCES:
patent: 5093317 (1992-03-01), Lewis et al.
patent: 5405942 (1995-04-01), Bell et al.
patent: 5473054 (1995-12-01), Jameson et al.
patent: 5476779 (1995-12-01), Chen et al.
patent: 6221842 (2001-04-01), Goldspink
patent: 0 309 050 (1989-03-01), None
patent: WO 89/05822 (1989-06-01), None
patent: WO 93/23067 (1993-11-01), None
Cambrey, A.D. et al., “Insulin-like growth factor I is a major fibroblast mitogen produced by primary cultures of human airway epithelial cells,”Clinical Science 89:611-617 (1995).
Duguay, S.J. et al., “Mutational Analysis of the Insulin-like Growth Factor I Prohormone Processing Site,”J. of Biol. Chem. 270(29):17566-17574 (1995).
Dugauay, S.J. et al., “Nucleotide Sequence and Tissue Distribution of Three Insulin-Like Growth Factor I Prohormones in Salmon,”Molecular Endocrinology, 6(8):1202-1210 (1992).
Green, M.W. and Ch en, T.T., Temporal expression pattern of insulin-like growth factor mRNa during embryonic development in a teleost, rainbow trout (Onchorynchus mykiss),Mol. Marine Biol. and Biotech. 6(2):144-151 (1997).
Hylka, V.W. and Straus, D.S., “The E-domain peptide of rat pro-insulin-like growth factor II (proIGF-II):properties of the peptide in serum and production by rat cell lines,”Biochimica et Biophysica Acta 1051:6-13 (1990).
Siegfried, J.M. et al., “A mitogenic peptide amide encoded within the E peptide domain of the insulin-like growth factor IB prohormone,”Proc. Natl. Acad. Sci. USA 89:8107-8111 (1992).
Shamblott, M.J. and Chen, T.T., “Age-related and tissue specific levels of five forms of insulin-like growth factor mRNA in a teleost,”Mol. Marine Biol. and Biotech. 2(6):351-361 (1993).
Wallis, A.E. and Devlin, R.H., “Duplicate Insulin-Like Growth Factor-I Genes in Salmon Display Alternative Splicing Pathways,”Mol. Endocrinology 7(3):409-422 (1993).
Zheng, J.L. et al., “Induction of Cell Proliferation by Fibroblast and Insulin-Like Growth Factors in Pure Rat Inner Ear Fibroblast Epithelial Cell Cultures,”J. Neurosci. 17(1):216-226 (Jan. 1, 1997).
Chen Maria J. M.
Chen Thomas T.
Kuo Ya-Huei
McCarter & English LLP
O'Hara Eileen B.
University of Connecticut
LandOfFree
Compositions and methods for inhibiting the proliferation... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for inhibiting the proliferation..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for inhibiting the proliferation... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3718101